RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
August 07, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
July 31, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
July 08, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 26, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
RM Primary Logo - Humble.png
Revolution Medicines to Participate in Upcoming Investor Conferences
February 01, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RM Primary Logo - Humble.png
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET | Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 31, 2023 16:15 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
RevolutionLogo.png
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 22, 2023 02:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...